

[1］中华医学会糖尿病学分会.基于胰高血糖素样肽1降糖药物的临床应用共识［J］.中华糖尿病杂志，2014，6(1)：14-20. 

[2］Thorens B，Waeber G.Glucagon-like peptide-I and the control of insulin secretion in the normal state and in NIDDM［J］.Diabetes，1993，42(9)：1219-1225. 

[3］Wei Y，Mojsov S.Tissue-specific expression of the human receptor for glucagon-like peptide-I：brain，heart and pancreatic forms have the same deduced amino acid sequences［J］.FEBS Lett，1995，358(3)：219-224. 

[4］Yamato E，Ikegami H，Takekawa K，et al.Tissue-specific and glucose-dependent expression of receptor genes for glucagon and glucagon-like peptide-1 (GLP-1) ［J］.Horm Metab Res，1997，29(2)：56-59. 

[5］Bunck MC，Diamant M，Corner A，et al.One-year treatment with exenatide improves beta-cell function，compared with insulin glargine，in metformin-treated type 2 diabetic patients：a randomized，controlled trial［J］.Diabetes Care，2009，32(5)：762-768. 

[6］Vilsboll T，Brock B，Perrild H，et al.Liraglutide，a once-daily human GLP-1 analogue，improves pancreatic B-cell function and arginine-stimulated insulin secretion during hyperglycaemia in patients with Type 2 diabetes mellitus［J］.Diabet Med，2008，25(2)：152-156. 

[7］Zinman B，Gerich J，Buse JB，et al.Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD) ［J］.Diabetes Care，2009，32(7)：1224-1230. 

[8］Russell-Jones D，Vaag A，Schmitz O，et al.Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU)：a randomised controlled trial［J］.Diabetologia，2009.52(10)：2046-2055. 

[9］DeFronzo RA，Ratner RE，Han J，Kim DD，Fineman MS，Baron AD.Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes.Diabetes Care，2005，28(5)：1092-1100. 

[10］Nauck M，Frid A，Hermansen K，et al.Efficacy and safety comparison of liraglutide，glimepiride，and placebo，all in combination with metformin，in type 2 diabetes：the LEAD (liraglutide effect and action in diabetes)-2 study［J］.Diabetes Care，2009，32(1)：84-90. 

[11］Garber A，Henry R，Ratner R，et al.Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono)：a randomised，52-week，phase Ⅲ，double-blind，parallel-treatment trial［J］.Lancet，2009，373(9662)：473-481. 

[12］Yang W，Chen L，Ji Q，et al.Liraglutide provides similar glycaemic control as glimepiride (both in combination with metformin) and reduces body weight and systolic blood pressure in Asian population with type 2 diabetes from China，South Korea and India：a 16-week，randomized，double-blind，active control trial［J］.Diabetes Obes Metab，2011，13(1)：81-88. 

[13］Ussher JR，Drucker DJ.Cardiovascular actions of incretin-based therapies［J］.Circ Res，2014，114(11)：1788-1803. 

[14］Drucker DJ，Buse JB，Taylor K，et al.Exenatide once weekly versus twice daily for the treatment of type 2 diabetes：a randomised，open-label，non-inferiority study［J］.Lancet，2008，372(9645)：1240-1250. 

[15］Wang B，Zhong J，Lin H，et al.Blood pressure-lowering effects of GLP-1 receptor agonists exenatide and liraglutide：a meta-analysis of clinical trials［J］.Diabetes Obes Metab，2013，15(8)：737-749. 

[16］Scholte M，Timmers L，Bernink FJ，et al.Effect of additional treatment with EXenatide in patients with an Acute Myocardial Infarction (EXAMI)：study protocol for a randomized controlled trial［J］.Trials，2011，12：240. 

[17］Kahn SE，Cooper ME，Del PS.Pathophysiology and treatment of type 2 diabetes：perspectives on the past，present，and future［J］.Lancet，2014，383(9922)：1068-1083. 

[18］Armstrong MJ，Houlihan DD，Rowe IA，et al.Safety and efficacy of liraglutide in patients with type 2 diabetes and elevated liver enzymes：individual patient data meta-analysis of the LEAD program［J］.Aliment Pharmacol Ther，2013，37(2)：234-242. 

[19］Owens DR，Monnier L，Bolli GB.Differential effects of GLP-1 receptor agonists on components of dysglycaemia in individuals with type 2 diabetes mellitus［J］.Diabetes Metab，2013，39(6)：485-496. 

[20］Kielgast U，Holst JJ，Madsbad S.Antidiabetic actions of endogenous and exogenous GLP-1 in type 1 diabetic patients with and without residual beta-cell function［J］.Diabetes，2011，60(5)：1599-1607. 

[21］Varanasi A，Bellini N，Rawal D，et al.Liraglutide as additional treatment for type 1 diabetes［J］.Eur J Endocrinol，2011，165(1)：77-84. 

[22］Shehadeh N，Daich E，Zuckerman-Levin N.Can GLP-1 preparations be used in children and adolescents with diabetes mellitus［J］.Pediatr Endocrinol Rev，2014，11(3)：324-327. 

[23］Li L，Shen J，Bala MM，et al.Incretin treatment and risk of pancreatitis in patients with type 2 diabetes mellitus：systematic review and meta-analysis of randomised and non-randomised studies［J］.BMJ，2014，348：g2366. 

[24］Devaraj S，Maitra A.Pancreatic Safety of Newer Incretin-Based Therapies：Are the “-tides” Finally Turning［J］.Diabetes，2014，63(7)：2219-2221. 